Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC).

Full DD Report for CYCC

You must become a subscriber to view this report.


Recent News from (NASDAQ: CYCC)

Cyclacel Pharmaceuticals' (CYCC) CEO Spiro Rombotis on Q1 2018 Results - Earnings Call Transcript
Cyclacel Pharmaceuticals, Inc. (CYCC) Q1 2018 Results Earnings Conference Call May 14, 2018, 04:30 PM ET Executives Alexander Fudukidis - IR Spiro Rombotis - President and CEO Paul McBarron - EVP, Finance and Chief Operating Officer Judy Chiao - VP of Clinical Development and R...
Source: SeekingAlpha
Date: May, 14 2018 20:24
Cyclacel Pharmaceuticals Reports First Quarter 2018 Financial Results
BERKELEY HEIGHTS, N.J., May 14, 2018 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) (NASDAQ:CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and othe...
Source: GlobeNewswire
Date: May, 14 2018 16:05
Cyclacel Pharmaceuticals to Release First Quarter 2018 Financial Results
BERKELEY HEIGHTS, N.J., May 08, 2018 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) (NASDAQ:CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and othe...
Source: GlobeNewswire
Date: May, 08 2018 07:00
Recent Analysis Shows Lancaster Colony, Calavo Growers, Acuity Brands, Cyclacel Pharmaceuticals, Enbridge Energy Management, and Nasdaq Market Influences - Renewed Outlook, Key Drivers of Growth
NEW YORK, May 04, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Lancaster Colony Corporation (NASDAQ:LANC), Calavo Growers, Inc. (NASDAQ:C...
Source: GlobeNewswire
Date: May, 04 2018 08:10
Cyclacel's CYC065 CDK Inhibitor Demonstrates Synergy With Venetoclax By Dual Targeting Of Chronic Lymphocytic Leukemia
BERKELEY HEIGHTS, N.J., April 17, 2018 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) (NASDAQ:CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutical company developing oral therapies that target various phases of cell cycle control for the treatment of cancer and other ...
Source: GlobeNewswire
Date: April, 17 2018 09:00
Cyclacel Announces Presentation of Phase 1 Clinical Data for CDK Inhibitor CYC065 at AACR 2018 Annual Meeting
BERKELEY HEIGHTS, N.J., April 16, 2018 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) (NASDAQ:CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and ot...
Source: GlobeNewswire
Date: April, 16 2018 07:00
Wired News - Stemline Therapeutics Initiates Rolling BLA Submission for SL-401
Stock Monitor: Cyclacel Pharma Post Earnings Reporting LONDON, UK / ACCESSWIRE / April 09, 2018 / Active-Investors.com has just released a free research report on Stemline Therapeutics, Inc. (NASDAQ: STML ) ("Stemline"). If you want access to this report all you need to do is sign up...
Source: ACCESSWIRE IA
Date: April, 09 2018 07:10
Cyclacel Pharmaceuticals' (CYCC) CEO Spiro Rombotis on Q4 2017 Results - Earnings Call Transcript
Cyclacel Pharmaceuticals, Inc. (CYCC) Q4 2017 Earnings Conference Call March 28, 2018, 16:30 ET Executives Alexander Fudukidis - IR Spiro Rombotis - CEO, President & Executive Director Paul McBarron - CFO, COO, EVP, Finance, Secretary & Executive Director Analysts J...
Source: SeekingAlpha
Date: March, 28 2018 22:16
Cyclacel Pharmaceuticals reports FY results
Cyclacel Pharmaceuticals (NASDAQ: CYCC ): FY EPS of -$1.95 Cash and cash equivalents of $23.91M Press Release More news on: Cyclacel Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, ,
Source: SeekingAlpha
Date: March, 28 2018 16:20
Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results
BERKELEY HEIGHTS, N.J., March 28, 2018 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) (NASDAQ:CYCCP) ("Cyclacel" or the "Company") a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and oth...
Source: GlobeNewswire
Date: March, 28 2018 16:05

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-05-171.3711.391.411.3767,059
2017-02-035.085.205.265.0234,909
2017-02-025.09994.985.144.82518,600
2017-02-014.695.125.144.6832,726
2017-01-314.724.754.754.6340,987

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-08-138501,90244.6898Short
2018-08-103,7104,63780.0086Short
2018-08-097258,6898.3439Cover
2018-08-084558,6715.2474Cover
2018-08-075,6629,86957.3716Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on CYCC.


About Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC)

Logo for Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC)

Not available

 

Contact Information

 

 

Current Management

  • Spiro Rombotis / President, CEO
  • Paul McBarron / COO
  • Corey Sohmer / IR

Current Share Structure

  • Market Cap: $16,556,477 - 05/15/2018
  • Issue and Outstanding: 11,997,447 - 03/27/2018

 


Recent Filings from (NASDAQ: CYCC)

Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 14 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 14 2018
Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: April, 12 2018
Additional proxy soliciting materials - definitive
Filing Type: DEFA14AFiling Source: edgar
Filing Date: April, 12 2018
Amendment to a previously filed Form 4
Filing Type: 4/AFiling Source: edgar
Filing Date: April, 12 2018
Annual report with a comprehensive overview of the company
Filing Type: 10-KFiling Source: edgar
Filing Date: March, 30 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 28 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 12 2018
Statement of beneficial ownership of common stock by certain persons
Filing Type: SC 13GFiling Source: edgar
Filing Date: February, 02 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: December, 12 2017

 

 


Daily Technical Chart for (NASDAQ: CYCC)

Daily Technical Chart for (NASDAQ: CYCC)


Stay tuned for daily updates and more on (NASDAQ: CYCC)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: CYCC)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in CYCC is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. DD Report does not own any shares of CYCC and does not buy, sell, or trade any shares of CYCC. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: http://dd.report/disclaimer/